Shares of Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) surged $4.45 to close at $14.25 on rival Intercept Pharmaceuticals Inc.’s (Nasdaq: ICPT) upbeat liver fibrosis treatment trial results. Conatus is developing a similar type of drug. Intercept stock leaped $169.96 to close at $445.83.
Conatus Soars On Rival’s Results
January 10, 2014 at 11:23 AM EST
